RSPH Logo Emory Logo
CONTACT . DIRECTORY . SEARCH . HOME

OPUS  . WEBMAIL  . BLACKBOARD  . CALENDAR 
 
 
RESEARCH


ICARE Home
Background
History of Project ICARE

Phase V (2005-2007)
Phase IV (2002-2004)
Phase III (1998-2000)
Phase II (1996-1997)
Phase I (1995)

Project ICARE Partners
ICARE Publications
ICARE Abstracts
Contact Us
 


Project ICARE: Abstracts

Abstracts in chronological order

2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995

1995

  1. Gaynes RP. Trends in antimicrobial resistance in the Intensive Care Unit. 5th Annual Meeting of the Society for Healthcare Epidemiology of America. San Diego, California, April 3, 1995; p8.

  2. Monnet D, Gaynes R, Tenover F, McGowan J, ICARE Pilot hospitals. Ceftazidime-resistant Pseudomonas aeruginosa and ceftazidime use in NNIS hospitals: preliminary results of Project ICARE Phase One. 5th Annual Meeting of the Society for Healthcare Epidemiology of America. San Diego, California, April 3, 1995; p. 19.

  3. Monnet D. Relationship between antibiotic resistance and antibiotic use. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, California, Sept 17, 1995, session 4B.

1996

  1. Archibald L, Phillips L, McGowan J, Monnet D, Tenover F, Gaynes R. Antimicrobial resistance in hospitals and outpatients in the United States: the increasing importance of the intensive care unit. 34th Meeting of the Infectious Disease Society of America. Infect Control Hosp Epidemiol 1996; 17(Pt 2):P30, abstract S1.

1997

  1. Archibald LK, Pryor ER, Mathema B, McGowan JE, Jr., Edwards, JR, Culver DH, Tenover F, Gaynes RP, and Project Intensive Care Antimicrobial Resistance Epidemiology (ICARE) hospitals, CDC, and Emory University. Antimicrobial resistance in U.S. hospitals: a comparison between inpatients and outpatient areas. 7th Annual Meeting of The Society for Healthcare Epidemiology of America. St. Louis, Missouri, April 1997, abstract M39.

  2. Archibald LK. Project ICARE-a practical approach to the question of antimicrobial use and resistance. Wellcome Trust Conference on Antimicrobial Resistance, Broadway, UK May 21-26, 1997.

  3. Fridkin SK, Edwards JR, Pryor ER, McGowan JE Jr, Mathema B, Tenover FC, Gaynes RP. Intensive Care Antimicrobial Epidemiology (ICARE) Hospitals. Impact of clinical practice guidelines on vancomycin use in intensive care units. 35th Annual Meeting of the Infectious Diseases Society of America, San Francisco, California, September 13-16, 1997, Presentation 574, abstract 764 (Late-breaker Session 129).

  4. Archibald LK, Edwards JR, Mathema BB, Pryor ER, McGowan JE, Jr, Culver DH, Tenover F, Gaynes RP, Project ICARE (Intensive Care Antimicrobial Resistance Epidemiology) Hospitals. Imipenem-resistance Pseudomonas aeruginosa in selected intensive care units in the United States. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, September 28-October 1, 1997, abstract J206, p. 327.
  5. Steward C, Stocker S, Swenson JM, O'Hara C, McGowan JE Jr, Lancaster MV, Tenover FC. Accuracy of the agar dilution, disk diffusion, MicroScan and Vitek systems for detection of fluoroquinolone resistance in Enterobacteriaceae. 97th Annual Meeting of the American Society for Microbiology, Miami Beach, Florida, May 4-8, 1997, abstract C490, p. 205.

  6. Tenover FC, Steward CD, Carson LA, Felicione EC, Mohammed J, McGowan JE Jr. Choosing molecular size standards for pulsed-field gel electrophoresis. Program of the Fourth International Meeting on Bacterial Epidemiological Markers, Elsinore, Denmark, September 10-13, 1997.

  7. Weigel LM, Steward CD, McGowan JE Jr, Tenover FC. gyrA mutations associated with fluoroquinolone resistance in multiple species of Enterobacteriaceae. Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, September 28-October 1, 1997, abstract J206, p. 327.

1998

  1. Fridkin SK, Pryor ER, Edwards JR, Archibald LK, Culver DH, McGowan JE, Jr, Pichette SC, Tenover F, Gaynes RP, ICARE Hospitals. Antimicrobial resistance in U.S. hospitals: comparison between inpatient and outpatient areas. International Conference on Emerging Infectious Diseases, Atlanta, Georgia, Mar 8-11, 1998.

  2. Pichette SC, Fridkin SK, Pryor ER, Edwards JR, Culver DH, McGowan JE, Jr., Tenover, F, Gaynes RP. Antimicrobial use and resistance in the U.S.: the importance of the type of intensive care unit. International Conference on Emerging Infectious Diseases. Atlanta, Georgia, Mar 8-11, 1998.

  3. Fridkin SK, Pryor ER, Edwards JR, McGowan JE, Jr., Gaynes RP. Do hospital antibiograms reflect resistance among infected patients? 8th Annual Meeting of The Society for Healthcare Epidemiology of America. Orlando, Florida, April 5-7, 1998.

  4. Fridkin SK, Edwards JR, Pichette SC, Pryor ER, McGowan JE, Jr., Culver DH, Tenover FC, Gaynes RP. Impact of clinical practice guidelines on vancomycin use in adult intensive care units at U.S. hospitals. 8th Annual Meeting of The Society for Healthcare Epidemiology of America. Orlando, Florida, April 5-7, 1998.

  5. Fridkin SK, Lawton RM, Gaynes RP, McGowan JE, JR., Tenover, F, and Intensive Care Antimicrobial Resistance Epidemiology (ICARE) Hospitals. Antimicrobial control practices at 47 U.S. hospitals: are we doing enough? 36th Annual Meeting of the Infectious Diseases Society of America, Denver, Colorado, November 12-15, 1998.

  6. Felicione EC, Steward CD, McGowan JE Jr, Tenover FC. Optimizing computer software for analysis of a vancomycin-resistant enterococci (VRE) pulsed-field gel electrophoresis (PFGE) library. Program of the International Emerging Infectious Diseases Conference, Atlanta, Georgia, March 8-11, 1998.

  7. Hubert SK, Steward CD, Tenover FC, McGowan JE Jr. Determination of a screening method for glycopeptide-intermediate Staphylococcus aureus (GISA) and other staphylococci using Mueller-Hinton agar. 8th Annual Meeting of the Society for Healthcare Epidemiology of America, Orlando, Florida, April 5-7, 1998.

  8. Mohammed JM, Steward CD, McGowan JE Jr, Tenover FC. Susceptibility patterns of recent isolates of vancomycin-resistant enterococci. Annual Meeting of the American Society for Microbiology, Atlanta, Georgia, May 17-21, 1998, abstract C-351, p. 189.

  9. Hubert SK, Steward CD, Mohammed JM, Fridkin SK, McGowan JE Jr, Tenover FC. Determination of a screening method for glycopeptide-intermediate Staphylococcus aureus (GISA) and other staphylococci using Mueller-Hinton agar and a survey of a nationwide sample of hosiptals. 98th Annual Meeting of the American Society for Microbiology, Atlanta, Georgia, May 17-21, 1998, abstract C-237, p. 170.

  10. Felicione EC, Steward CD, Fridkin SK, Tenover FC, McGowan JE Jr. Geographic region in the US as a risk factor for clonality among nosocomial isolates of vancomycin-resistant Enterococcus faecium and Enterococcus faecalis. Annual Meeting of the American Society for Microbiology, Atlanta, Georgia, May 17-21, 1998, abstract C-355, p. 190.

  11. Steward CD, McGowan JE Jr., Tenover FC, Fridkin SK, Gaynes RP, Project ICARE Hospitals. CDC and Rollins School of Public Health of Emory University. Multicenter Study of Susceptibility of Imipenem Demonstrates That Testing Problems Persist. 36th Annual Meeting of Infectious Diseases Society of America, Denver, Colorado, November 12-15, 1998.

1999

  1. Fridkin SK, Edwards JR, Tenover FC, Gaynes RP, McGowan JE Jr., and the Intensive Care Antimicrobial Resistance Epidemiology (ICARE) Project Hospitals. Correlation of vancomycin-resistant enterococci (VRE) prevalence and parenteral antimicrobial use in 108 adult intensive care units (ICUs) at 41 U.S. hospitals. 9th Annual Meeting of The Society for Healthcare Epidemiology of America, San Francisco, California. April 18-20, 1999.

  2. Lawton RM, Fridkin SK, Edwards JR, Tenover FC, Gaynes RP, McGowan JE Jr., and the Intensive Care Antimicrobial Resistance Epidemiology (ICARE) Project Hospitals. Institutional determinants of ceftazidime use and the impact of guidelines for appropriate use in 108 adult intensive care units (ICUs) at 41 U.S. hospitals. 9th Annual Meeting of The Society for Healthcare Epidemiology of America, San Francisco, California. April 18-20, 1999.

  3. Steward CD, Mohammed JM, Stocker SA, Swenson JM, Gaynes RP, McGowan JE, Jr., Tenover FC, Hospital Infections Program, CDC, and Rollins School of Public Health of Emory University, Atlanta, GA. Accuracy of six antimicrobial test systems for detecting resistance to imipenem and meropenem in Enterobacteriaceae and Pseudomonas aeruginosa. Annual Meeting of the American Society for Microbiology, Chicago, Illinois. May 30-June 3, 1999.

  4. Wallace D, Steward CD, Hubert SK, Lawton R, Fridkin SK, Gaynes RP, McGowan JE, Jr., Tenover FC, and Project ICARE Hospitals, Rollins School of Public Health of Emory University and CDC, Atlanta, GA. Ability of laboratories to detect emerging antimicrobial resistance in nosocomial pathogens. Annual Meeting of the American Society for Microbiology, Chicago, Illinois. May 30-June3, 1999.

  5. Steward CD, Hubert SK, Williams PP, Biddle JW, McGowan, Jr. JE, Tenover FC. Validation of National Committee for Clinical Laboratory Standards (NCCLS) Extended-Spectrum ?-lactamase (ESBL) detection method using clinical isolates of Klebsiella pneumoniae. 39th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, California. September 26-29, 1999.

  6. McGowan JE Jr. Susceptibility testing and antibiotic usage - controls and cooperation in the clinical microbiology laboratory. Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, California, September 26-29, 1999, abstract 2022.

2000

  1. Ostrowsky BE, Lawton R, Fridkin S, Gaynes R. Antimicrobial use in
    hematology/oncology units differs from use in other hospital wards. 4th Decennial International Conference on Nosocomial and Healthcare-Associated Infections, Atlanta, Georgia. March 5-9, 2000.

  2. Coignard B, Fridkin SK, Hill H, Lawton R, Edwards J, McGowan JE, Tenover FC, Gaynes RP. Does resistance among nosocomial pathogens differ between pediatric and adult intensive care units? 4th Decennial International Conference on Nosocomial and Healthcare-Associated Infections, Atlanta, Georgia. March 5-9, 2000.

  3. Lawton RM, Fridkin SK, Hill H, Gaynes RP, Edwards J, McGowan JE, Jr. Impact of national benchmarks on quality improvement and vancomycin use. 4th Decennial International Conference on Nosocomial and Healthcare-Associated Infections, Atlanta, Georgia. March 5-9, 2000.

  4. Pryor E, Fridkin S, Kleinbaum D, McGowan J, Jr., Gaynes R, Phase 2 Project Intensive Care Antimicrobial Resistance Epidemiology (ICARE) Hospitals. Factors associated with ceftazidime (CTZ) resistance in Pseudomonas aeruginosa (PA) isolates in 29 U.S. hospitals. 4th Decennial International Conference on Nosocomial and Healthcare-Associated Infections, Atlanta, Georgia. March 5-9, 2000.

  5. McGowan JE Jr. 24th Sir F. Macfarlane Burnet Oration: Control of antimicrobial use and resistance in the health care system. Annual Scientific Meeting of the Australasian Society for Infectious Diseases, Leura, New South Wales, Australia, April 15-19, 2000.

  6. McGowan JE Jr. Vancomycin intermediate S. aureus (VISA). Western Australia Seminar in Antibiotics and Infection Control, Fremantle, Western Australia, April 26-27, 2000.

  7. McGowan JE Jr. The epidemiology of multi-resistant gram-negative organisms. Western Australia Seminar in Antibiotics and Infection Control, Fremantle, Western Australia, April 26-27, 2000.

  8. Volkova N, McGowan J, Hill H, Lawton R, Fridkin S, Edwards J, Tenover F, Gaynes R, Project ICARE Hospitals. Recent changes in antimicrobial resistance in US hospitals: A report from Project ICARE. 38th Annual Meeting of the Infectious Disease Society of America, New Orleans, Louisiana, September 7-10, 2000.

  9. Volkova N, McGowan J, Hill H, Lawton R, Tenover F, Gaynes R, Project ICARE Hospitals. Does resistance cluster in individual hospitals? 38th Annual Meeting of the Infectious Diseases Society of America, New Orleans, Louisiana, September 7-10, 2000.

  10. Pryor ER, Fridkin SK, Kleinbaum DG, Tenover FC, Gaynes RP, McGowan JE Jr., Phase 2 Project ICARE Hospitals. Institutional factors associated with third generation cephalosporin resistance in Klebsiella pneumoniae isolates from 26 US hospitals. 38th Annual Meeting of the Infectious Disease Society of America, New Orleans, Louisiana, September 7-10, 2000.

  11. McGowan JE Jr, Quinn JP, Gelone S. Optimizing therapeutic strategies to minimize the impact of emerging resistance in intensive care. Program of the 29th Educational and Scientific Symposium, Society of Critical Care Medicine, Orlando, Florida, February 12, 2000, page 36.

  12. Tenover FC, Raney PM, Williams PP, Britain KL, Steward CD, Fridkin SK, Gaynes RP, McGowan JE Jr. Mechanisms of extended-spectrum cephalosporin resistance in Escherichia coli isolates from 26 United States hospitals collected during Project ICARE. Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Toronto, Canada, September 17-20, 2000, abstract 1606.

  13. Raney PM, Williams PP, McGowan JE Jr, Tenover FC. Validation of the new Vitek version 7.01 software for detecting staphylococci with reduced susceptibility to vancomycin. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Toronto, Canada, September 17-20, 2000, abstract 1624.

2001

  1. McGowan JE Jr. Antibiotics in the ICU: the patient vs. the community - a dilemma. Program of the 30th International Educational and Scientific Symposium, Society of Critical Care Medicine, February 10-14, 2001, San Francisco, California, page 53.

  2. McGowan JE Jr. Efforts to control antimicrobial resistance - what works? 11th Annual Meeting of the Society for Healthcare Epidemiology of America, Toronto, Canada, April 1-3, 2001, session P-III, page 14.

  3. McGowan JE Jr. Worldwide consequences of bacterial resistance - lessons from Project ICARE. Annual Meeting of the Swiss Infectious Diseases Society, Lausanne, Switzerland, May 10, 2001.

  4. Smith A, McLay C, Lawton R, Fridkin S, McGowan J, Gaynes R. Monitoring of soap, glove, gown, and paper towel use in intensive care units. 28th Annual Educational Conference and Educational Meeting of the Association for Professionals in Infection Control and Epidemiology, Seattle, Washington, June 10-14, abstract 52.

  5. Duck WM, Steward CD, McGowan JE Jr, Tenover FC. Comparison of molecular weight (MW) and Retardation factor (Rf) methods for software-based analysis of pulsed-field gel electrophoresis (PFGE) patterns. 101st General Meeting of the American Society for Microbiology, Orlando, FL, May 20-24, 2001, abstract L-17.

  6. Duck WM, Steward CD, McGowan JE Jr, Tenover FC. Optimizing matching tolerance algorithms in software programs that analyze chromosomal DNA restriction fragment patterns generated by pulsed-field gel electrophoresis (PFGE). 101st General Meeting of the American Society for Microbiology, Orlando, FL, May 20-24, 2001, Abstract L-19.

  7. Yigit H, Anderson GJ, Biddle JW, Steward CD, Tenover FC. Imipenem resistance in Enterobacter aerogenes is associated with loss of a 42 kDA porin. 101st General Meeting of the American Society for Microbiology, Orlando, FL, May 20-24, 2001, Abstract A-96, page 23.

  8. Hill HA, Haber MJ, McGowan JE Jr, Fridkin SK, Edwards JR, Tenover FC, Gaynes RP, Project ICARE Hospitals. A link between quinolone use and resistance in P. aeruginosa? Program and abstracts of the 39th Annual Meeting of the Infectious Diseases Society of America, San Francisco, California, October 25-28, 2001, abstract 495, page 124.

  9. Jevitt LA, Smith AJ, Williams PP, Fridkin SK, McGowan JE Jr, Gaynes PR, Tenover FC, Project ICARE Hospitals. In vitro activities of daptomycin, linezolid, and quinupristin-dalfopristin against a challenge panel of staphylococci and enterococci, including vancomycin-intermediate S. aureus (VISA) and vancomycin-resistant Enterococcus faecium (VREF). Program and abstracts of the 39th Annual Meeting of the Infectious Diseases Society of America, San Francisco, California, October 25-28, 2001, abstract 535, page 130.

  10. McGowan JE Jr. How to assess the impact of antibiotic use and of policies on bacterial resistance in hospitals. Program of the European Conference on Antibiotic Use, Brussels, Belgium, November 15-17, 2001, page 4.

  11. Duck WM, Steward CD, Kellum M, McGowan JE Jr, Tenover FC. Optimizing matching tolerance algorithms in software programs that analyze pulsed-field gel electrophoresis (PFGE) patterns for S. aureus (abstract C2-303). 41st Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Illinois, December 16-18, 2001, page 120.

  12. Oliver A, McGowan JE Jr, Tenover FC. Mechanisms of low-level cefpodoxime resistance in Escherichia coli. (abstract D-177). 41st Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Illinois, December 16-18, 2001, page 153.

  13. Raney PM, Williams PP, McGowan JE Jr, Tenover FC. Evaluation of the NCCLS disk diffusion screening test for extended-spectrum beta-lactamase (ESBL) production in Escherichia coli (abstract D-182). 41st Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Illinois, December 16-18, 2001, page 155.

2002

  1. McGowan JE Jr. Antimicrobial resistance – global consequences for public health. 129th Annual Meeting of the American Public Health Association, Atlanta, Georgia, October 21-25, 2002.

  2. McGowan JE Jr. Guidelines for control of glycopeptide-resistant enterococci have not yet worked. 5th Annual Meeting of the Hospital Infection Society, Edinburgh, Scotland, September 17-19, 2002.

  3. McGowan JE Jr. Antibiotic-resistant bacterial infections: implications for China from Project ICARE. International Medical Forum on Infectious Disease, China Medical Foundation, Beijing, May 29-31, 2002.

  4. Schwaber MJ, Raney PM, Rasheed JK, Biddle JM, McGowan JE Jr., Tenover FC. Testing for extended-spectrum beta-lactamases in isolates of Enterobacteriaceae other than Escherichia coli and Klebsiella pneumoniae (abstract D-526). 42nd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, California, September 27-30, 2002.

  5. Steward CD, Williams PP, McGowan JE Jr, Tenover FC. Accuracy of the Vitek 2 for detecting and reporting resistance for isolates of Klebsiella pneumoniae and Escherichia coli (abstract D-526). 42nd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, California, September 27-30, 2002.

  6. Ryan KA, Steward CD, Tenover FC, McGowan JE Jr. Association between carbapenem and fluoroquinolone resistance among Project ICARE Pseudomonas aeruginosa isolates (abstract C2-306). 42nd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, California, September 27-30, 2002.

  7. Ryan KA, Williams PP, Steward CD, McGowan JE Jr., Tenover FC. Screening of carbapenem-resistant Pseudomonas aeruginosa isolates from 25 United States hospitals for the presence of carbapenemases. 40th Annual Meeting of the Infectious Diseases Society of America, Chicago, October 24-27, 2002

2003

  1. Huskins C, Wallace D, Marquis C, Lipsitch M, Cooper B, Fridkin S, McGowan JE, Samore M, Goldmann DA. Cluster-randomized trials of interventions to reduce antimicrobial resistance in hospitals. National Foundation for Infectious Diseases 2003 Annual Conference on Antimicrobial Resistance, Bethesda, Maryland, June 23-25, 2003.

  2. Tenover FC. Pulsed-field typing of oxacillin-resistant Staphylococcus aureus: the American experience. Sixth International Conference on Microbial Epidemiologic Markers, Les Diablerets, Switzerland, August 27-30, 2003.

  3. McGowan JE Jr. Monitoring and evaluating antibiotic use in healthcare facilities by stratum: the Project ICARE experience. 43rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Illinois, September 14-17, 2003, Pre-meeting workshop 43-08, p. 8.

  4. Tenover FC, Caiaffa-Filho HH, Mimica L, Williams PP, Jevitt L, Tehan M, Raney PM, McGowan JE Jr. A targeted proficiency testing program enhances laboratory surveillance for uncommon extended-spectrum ß-lactamases (ESBLs). 43rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Illinois, September 14-17, 2003, abstract D-196, p. 16.

  5. Tenover FC. Challenging bacterial resistance issues: VRE, vancomycin-tolerant Streptoccocus pneumoniae, inducible lincosamide resistance, ESBLs. 43rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Illinois, September 14-17, 2003, abstract 2073, p. 131.

  6. McGowan JE Jr. Cost of Resistance: Now a crucial part of formulary decisions. 43rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Illinois, September 14-17, 2003, abstract 2090, p. 133.

  7. McGowan JE Jr. Epidemiology of antibiotic consumption and the frequency of antibiotic resistance. 41st Annual Meeting of the Infectious Diseases Society of America, San Diego, California, October 9-12, 2003, abstract 118, p. 35-36.

  8. Tenover FC.VRSA, VISA, and CMRSA: staphylococcal alphabet soup. 41st Annual Meeting of the Infectious Diseases Society of America, San Diego, California, October 9-12, 2003, abstract 950, p. 27.

  9. McGowan JE Jr. Does antimicrobial resistance cluster in individual hospitals? 41st Annual Meeting of the Infectious Diseases Society of America, San Diego, California, October 9-12, 2003, abstract 1004, p. 39.

  10. McGowan JE Jr. Antibiotic-resistant bacterial infections: implications for China from Project ICARE. International Medical Forum on Infectious Disease, China Medical Foundation, Beijing, May 29-31, 2002.

2004

  1. McGowan JE Jr. The status of antimicrobial resistance. American College of Clinical Pharmacy Annual Meeting, Atlanta, Georgia, November 3, 2004, session 117.

  2. McGowan JE Jr (Co-Moderator): Seminar - Mathematical modeling and public health policy - responding to public health crises." Third International Conference on Emerging Infectious Diseases 2004, Atlanta, Feb 29-March 3, 2004, session 73.

  3. McGowan JE Jr. Antimicrobial resistance and its relationship to antimicrobial use. 9th Annual Congress of the European Association of Hospital Pharmacists, Seville, Spain, March 17-19, 2004, abstract 17.

  4. McGowan JE Jr. How reliable are microbiology data on antimicrobial resistance? Infection 2004; Conference on Maximizing the Probabilities of Positive Outcomes, Dallas, Texas, April 21, 2004.

  5. McGowan JE Jr. Problem organisms. Training course in healthcare epidemiology, Society for Healthcare Epidemiology of America, Boston, Massachusetts, May 21, 2004.

  6. Raney PM, Tenover FC, Carey RB, McGowan JE Jr, Patel JB. Detection of inducible clindamycin and telithromycin resistance in isolates of beta-hemolytic streptococci. 104th Annual Meeting of the American Society for Microbiology, New Orleans, Louisiana, May 23-27, 2004, abstract C-126.

  7. Zhu W, Tenover FC, Jackson MA, Dunne WM, McGowan JE Jr, Patel JB. Characterization of linezolid-resistant Staphylococcus aureus isolates. 104th Annual Meeting of the American Society for Microbiology, New Orleans, Louisiana, May 23-27, 2004, abstract A-109.

  8. Barlow M, Tenover, FC, McGowan JE Jr. The origin of the CTX-Ms. 104th Annual Meeting of the American Society for Microbiology, New Orleans, Louisiana, May 23-27, 2004, abstract A-121.

  9. Wu J, McGowan JE Jr, Howard DH, Frau LM, Dai WS. Impact of macrolide antibiotic treatment failure on healthcare utilization in patients with acute bronchitis. 37th Annual Meeting of the Society for Epidemiologic Research, Salt Lake City, Utah, June 15-18, 2004, abstract 165 (published in Amer J Epidemiol 2004; 159(12): S40.

  10. Jevitt L, Patel J, McGowan JE Jr, Tenover FC. Evaluation of FDA-approved disk diffusion breakpoint for daptomycin, 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, D.C., October 30-Nov 2, 2004, abstract D-48.

  11. Welsh K, Barlow M, Tenover FC, Biddle JW, Rasheed JK, Clark LA, McGowan JE Jr. Experimental prediction of the evolution of ceftazidime resistance in the CTX-M-2 extended-spectrum beta-lactamase, 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, D.C., October 30-Nov 2, 2004, abstract C1-1660.

2005

  1. Rao AN, Barlow M, Clark LA, Tenover FC, McGowan JE Jr. Association of antibiotic resistance phenotypes and the presence of class I integronsin a sample of bacterial isolates from U.S. hospitals. 15th European Congress of Clinical Microbiology and Infectious Diseases, Copenhagen, Denmark, April 2-5, 2005, abstract P-1067. Clin Microbiol Infect 2005; 11(Suppl 2):332. [Abstract]

  2. Welsh KJ, Barlow M, Williams PP, McGowan JE, Jr, Tenover FC. Inability to select for high-level fluoroquinolone (FQ) resistance after in vitro mutagenesis of qnr. 105th Annual Meeting of the American Society for Microbiology, Atlanta, Georgia, June 5-9, 2005, abstract A-003. [Abstract]

2006

  1. Tenover FC, Vaughn RR, McDougal LK, Fosheim G, McGowan JE JR. Multiple locus variable number tandem repeat assays (MLVA) do not differentiate between community-associated and healthcare-associated lineages of methicillin-resistant Staphylococcus aureus (MRSA). 16 th European Congress of Clinical Microbiology and Infectious Diseases, Nice France, April 1-4, 2006, abstract O-172. [abstract]

  2. Stone N, O'Hara C, Williams P, McGowan JE Jr, Tenover F. Susceptibility testing of unusual species of Enterobacteriaceae: comparison of disk diffusion, VITEK 2, and broth microdilution. 16 th European Congress of Clinical Microbiology and Infectious Diseases, Nice France, April 1-4, 2006, abstract P-447. [abstract]

  3. Huang V, Tenover FC, McGowan JE Jr. Detecting Staphylococcus aureus isolates with reduced vancomycin susceptibility. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, California, September 27-30, 2006, Abstract D811, session 86. [abstract]

2007

  1. Stone ND, Lewis DR, Nagamia Z, Lowery K, Clairmont J, Johnson TM II, McGowan JE Jr, Tenover  FC, Jernigan JA, Richards CL, Gaynes RP. Methicillin-resistant Staphylococcus aureus carriage in a long-term care facility: stability after one year. 17th Ann Meeting of Society for Healthcare Epidemiology of America, Baltimore, MD, April 14-17, abstract 82, page 86. [abstract]

  2. Huang V, Tenover FC, McGowan JE Jr. Evaluation of Etest GRD for detecting reduced vancomycin susceptibility among clinical isolates of Staphylococcus aureus. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Illinois, September 17-20, 2007, abstract D-888, page 166. [abstract]

Back to top

PHASE V OF PROJECT ICARE IS SPONSORED IN PART BY:

AstraZeneca    Elan     J&J PRD     Pfizer     3M Health Care


© 2005 ICARE, All rights reserved.
For all problems or questions regarding this website
please contact Dr. John McGowan at jmcgowa@sph.emory.edu











Home | About RSPH | Academics | Departments | Prospective Students | Current Students | Alumni Site Map | Intranet  






©  Emory University. The Robert W. Woodruff Health Sciences Center.   2012 .  All Rights Reserved.